NCT02271438View on ClinicalTrials.gov

A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

May 31, 2015

Conditions
Healthy
Interventions
DRUG

Ibrutinib

Participants will receive a single oral dose of 12 capsules (12\*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6\*140 mg capsules) of ibrutinib in Treatment B.

DRUG

Moxifloxacin

Participants will receive a single oral dose of 1 moxifloxacin capsule (400 mg) in Treatment D.

DRUG

Ibrutinib-matching placebo

Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.

DRUG

Moxifloxacin-matching placebo

Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02271438 - A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants | Biotech Hunter | Biotech Hunter